If Merck were to acquire NWBO and gain exclusive rights to DCVax-L, they could potentially create and market a combination therapy like "Keytruda+" that integrates DCVax-L with Keytruda. This strategy could allow Merck to leverage NWBO's robust patent portfolio for DCVax-L to protect the new combo therapy from competitors. By doing so, Merck could extend exclusivity for the combination drug, even after Keytruda's patent expires. This only makes sense with a Merck buyout. Perhaps that is what the Keytruda/DCVax-L trial was about.
This is all speculation on my part. I have no knowledge in this area. It would be interesting what the big boys, including you, and girls have to say about it. Does it make sense?
Market Data 
Markets 
AI
